JP7225089B2 - 接触活性化系に関連する疾患のタンパク質バイオマーカー - Google Patents

接触活性化系に関連する疾患のタンパク質バイオマーカー Download PDF

Info

Publication number
JP7225089B2
JP7225089B2 JP2019514252A JP2019514252A JP7225089B2 JP 7225089 B2 JP7225089 B2 JP 7225089B2 JP 2019514252 A JP2019514252 A JP 2019514252A JP 2019514252 A JP2019514252 A JP 2019514252A JP 7225089 B2 JP7225089 B2 JP 7225089B2
Authority
JP
Japan
Prior art keywords
protein
hae
subject
disease
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019514252A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529906A (ja
JP2019529906A5 (cg-RX-API-DMAC7.html
Inventor
セクストン，ダニエル，ジェー．
ヴィスワナサン，マリーニ
フォーセット，ライアン
ガウル，トゥリプティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2019529906A publication Critical patent/JP2019529906A/ja
Publication of JP2019529906A5 publication Critical patent/JP2019529906A5/ja
Priority to JP2023017816A priority Critical patent/JP7412616B2/ja
Application granted granted Critical
Publication of JP7225089B2 publication Critical patent/JP7225089B2/ja
Priority to JP2023218832A priority patent/JP7693788B2/ja
Priority to JP2025094023A priority patent/JP2025124852A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2019514252A 2016-09-16 2017-09-15 接触活性化系に関連する疾患のタンパク質バイオマーカー Active JP7225089B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2023017816A JP7412616B2 (ja) 2016-09-16 2023-02-08 接触活性化系に関連する疾患のタンパク質バイオマーカー
JP2023218832A JP7693788B2 (ja) 2016-09-16 2023-12-26 接触活性化系に関連する疾患のタンパク質バイオマーカー
JP2025094023A JP2025124852A (ja) 2016-09-16 2025-06-05 接触活性化系に関連する疾患のタンパク質バイオマーカー

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662395712P 2016-09-16 2016-09-16
US62/395,712 2016-09-16
US201762518492P 2017-06-12 2017-06-12
US62/518,492 2017-06-12
PCT/US2017/051749 WO2018053244A1 (en) 2016-09-16 2017-09-15 Protein biomarkers for diseases associated with the contact activation system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023017816A Division JP7412616B2 (ja) 2016-09-16 2023-02-08 接触活性化系に関連する疾患のタンパク質バイオマーカー

Publications (3)

Publication Number Publication Date
JP2019529906A JP2019529906A (ja) 2019-10-17
JP2019529906A5 JP2019529906A5 (cg-RX-API-DMAC7.html) 2020-11-12
JP7225089B2 true JP7225089B2 (ja) 2023-02-20

Family

ID=59974881

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019514252A Active JP7225089B2 (ja) 2016-09-16 2017-09-15 接触活性化系に関連する疾患のタンパク質バイオマーカー
JP2023017816A Active JP7412616B2 (ja) 2016-09-16 2023-02-08 接触活性化系に関連する疾患のタンパク質バイオマーカー
JP2023218832A Active JP7693788B2 (ja) 2016-09-16 2023-12-26 接触活性化系に関連する疾患のタンパク質バイオマーカー
JP2025094023A Pending JP2025124852A (ja) 2016-09-16 2025-06-05 接触活性化系に関連する疾患のタンパク質バイオマーカー

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2023017816A Active JP7412616B2 (ja) 2016-09-16 2023-02-08 接触活性化系に関連する疾患のタンパク質バイオマーカー
JP2023218832A Active JP7693788B2 (ja) 2016-09-16 2023-12-26 接触活性化系に関連する疾患のタンパク質バイオマーカー
JP2025094023A Pending JP2025124852A (ja) 2016-09-16 2025-06-05 接触活性化系に関連する疾患のタンパク質バイオマーカー

Country Status (13)

Country Link
US (2) US11815516B2 (cg-RX-API-DMAC7.html)
EP (1) EP3513196A1 (cg-RX-API-DMAC7.html)
JP (4) JP7225089B2 (cg-RX-API-DMAC7.html)
KR (3) KR102806918B1 (cg-RX-API-DMAC7.html)
CN (2) CN109716138B (cg-RX-API-DMAC7.html)
AU (2) AU2017325983B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019005179A2 (cg-RX-API-DMAC7.html)
CA (1) CA3037154A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019002599A2 (cg-RX-API-DMAC7.html)
IL (2) IL265195B2 (cg-RX-API-DMAC7.html)
MX (2) MX2019002932A (cg-RX-API-DMAC7.html)
NZ (1) NZ792394A (cg-RX-API-DMAC7.html)
WO (1) WO2018053244A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019005167A2 (pt) 2016-09-16 2019-07-02 Dyax Corp. método e kit para analisar uma amostra
CN113092769A (zh) * 2019-12-23 2021-07-09 首都医科大学附属北京世纪坛医院 尿液补体c4-a及其多肽片段在过敏性疾病中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001174463A (ja) 1999-12-17 2001-06-29 Hsp Research Institute Inc 自己免疫疾患又は腫瘍の診断方法
JP2012501184A (ja) 2008-08-28 2012-01-19 ワイス・エルエルシー 自己免疫疾患におけるｉｌ−２２、ｉｌ−１７、およびｉｌ−１ファミリーのサイトカインの使用
WO2015061183A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
WO2015112578A1 (en) 2014-01-21 2015-07-30 Dyax Corp. Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
JP2016511823A (ja) 2013-01-20 2016-04-21 ダイアックス コーポレーション ブラジキニン媒介障害の評価および治療

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ES2227545T3 (es) 1994-01-11 2005-04-01 Dyax Corporation Proteinas y sus analogos del "dominio de kunitz" inhibidores de calicreina.
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
DE60333758D1 (de) 2002-06-07 2010-09-23 Dyax Corp Prevention und Verringerung von Ischemia
JP4399593B2 (ja) * 2004-04-01 2010-01-20 国立大学法人 千葉大学 インフルエンザ脳症の検査法、及び、ヒト髄液中に発現するタンパク質からなるマーカ、診断薬、診断キット
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
US8841259B2 (en) * 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
GB2428240A (en) * 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
CA2630838A1 (en) 2005-11-23 2007-05-31 Georg Dewald Detection and treatment of drug associated angioedema
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US20090104605A1 (en) * 2006-12-14 2009-04-23 Gary Siuzdak Diagnosis of sepsis
US8883153B2 (en) 2009-03-27 2014-11-11 The Research for The State University of New York Methods for preventing and treating angioedema
SI3459564T1 (sl) 2010-01-06 2022-06-30 Takeda Pharmaceutical Company Limited Proteini, ki vežejo plazemski kalikrein
US9102942B2 (en) 2010-02-04 2015-08-11 EWHA University—Industry Collaboration Foundation Pharmaceutical composition for inhibiting abnormal proliferation of cells
JP2011226882A (ja) * 2010-04-19 2011-11-10 Kitasato Institute 泌尿器系疾患マーカー及びその抗体、並びに泌尿器系疾患診断用キット
JP2014506257A (ja) 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
WO2012170947A2 (en) * 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
US20130102486A1 (en) * 2011-10-20 2013-04-25 The Board Of Trustees Of The Leland Stanford Junior University Perp as a prognostic and diagnostic marker for dysplasia and cancer
JP6656926B2 (ja) * 2013-01-20 2020-03-04 ダイアックス コーポレーション ｐＫａｌ関連疾病の評価、アッセイおよび治療
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
US10101344B2 (en) * 2013-10-21 2018-10-16 Dyax Corp. Diagnosis and treatment of autoimmune diseases
CA2940585C (en) * 2014-04-15 2023-08-08 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Differential diagnosis of eczema and psoriasis
BR112019005167A2 (pt) 2016-09-16 2019-07-02 Dyax Corp. método e kit para analisar uma amostra
IL315175A (en) 2016-09-16 2024-10-01 Takeda Pharmaceuticals Co RNA biomarkers for hereditary angioedema

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001174463A (ja) 1999-12-17 2001-06-29 Hsp Research Institute Inc 自己免疫疾患又は腫瘍の診断方法
JP2012501184A (ja) 2008-08-28 2012-01-19 ワイス・エルエルシー 自己免疫疾患におけるｉｌ−２２、ｉｌ−１７、およびｉｌ−１ファミリーのサイトカインの使用
JP2016511823A (ja) 2013-01-20 2016-04-21 ダイアックス コーポレーション ブラジキニン媒介障害の評価および治療
WO2015061183A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
WO2015112578A1 (en) 2014-01-21 2015-07-30 Dyax Corp. Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OHSAWA, Isao et al.，Clinical and Laboratory Characteristics That Differentiate Hereditary Angioedema in 72 Patients with Angioedema，Allergology International，2014年，Vol.63，pp.595-602

Also Published As

Publication number Publication date
US20240142468A1 (en) 2024-05-02
US11815516B2 (en) 2023-11-14
KR20250073510A (ko) 2025-05-27
JP2025124852A (ja) 2025-08-26
IL265195B1 (en) 2024-10-01
BR112019005179A2 (pt) 2019-07-02
JP7412616B2 (ja) 2024-01-12
CN109716138A (zh) 2019-05-03
KR20230044024A (ko) 2023-03-31
MX2019002932A (es) 2019-07-15
CN109716138B (zh) 2023-10-03
JP7693788B2 (ja) 2025-06-17
IL265195A (en) 2019-05-30
WO2018053244A1 (en) 2018-03-22
JP2019529906A (ja) 2019-10-17
JP2024023904A (ja) 2024-02-21
CA3037154A1 (en) 2018-03-22
AU2017325983A1 (en) 2019-03-21
NZ751193A (en) 2024-02-23
KR102513485B1 (ko) 2023-03-23
NZ792394A (en) 2025-07-25
EP3513196A1 (en) 2019-07-24
JP2023058608A (ja) 2023-04-25
AU2024201506A1 (en) 2024-03-28
CO2019002599A2 (es) 2019-03-29
US20210285962A1 (en) 2021-09-16
IL265195B2 (en) 2025-02-01
KR102806918B1 (ko) 2025-05-14
IL315799A (en) 2024-11-01
AU2024201506B2 (en) 2025-12-18
AU2017325983B2 (en) 2023-12-07
CN117192130A (zh) 2023-12-08
MX2024009782A (es) 2024-08-19
KR20190053913A (ko) 2019-05-20

Similar Documents

Publication Publication Date Title
JP7516451B2 (ja) ｐＫａｌ関連疾病の評価、アッセイおよび治療
JP7692508B2 (ja) 接触活性化系に関連する疾患の代謝物バイオマーカー
JP2025124852A (ja) 接触活性化系に関連する疾患のタンパク質バイオマーカー
JP2025522757A (ja) ラナデルマブ治療のためのタンパク質バイオマーカー
EA045712B1 (ru) Белковые биомаркеры заболеваний, ассоциированных с контактной системой активации

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200914

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211203

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221020

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230208

R150 Certificate of patent or registration of utility model

Ref document number: 7225089

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150